<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518502</url>
  </required_header>
  <id_info>
    <org_study_id>2012AS0313</org_study_id>
    <nct_id>NCT03518502</nct_id>
  </id_info>
  <brief_title>Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis</brief_title>
  <official_title>Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Liver Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic
      metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be
      beneficial for controlling intrahepatic tumour. The investigators aimed to compare the
      efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC
      patients with EHM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic
      metastasis (EHM). However, transarterial chemoembolization (TACE) which is a standard therapy
      for intermediate stage may be beneficial for controlling intrahepatic tumour, thereby
      providing chance of improving survival in HCC patients with EHM.

      The investigators aimed to compare the efficacy between the sorafenib monotherapy and
      TACE-sorafenib sequential therapy in HCC patients with EHM.

      This study is a prospective randomized controlled study being conducted at 6 tertiary
      hospitals in South Korea. HCC patients with EHM are being enrolled and randomized into
      sorafenib monotherapy or TACE-sorafenib sequential therapy group. Patients with main portal
      vein invasion, Child-Pugh class B or C, and history of TACE or previous systemic therapy are
      being excluded. The sorafenib monotherapy group receives sorafenib immediately after
      randomization while the TACE-sorafenib group receives 2~4 times of TACE before starting
      sorafenib. Response evaluation are performed every 2 months, and time to progression (TTP),
      progression free survival (PFS), median survival time (MST), and overall survival (OS) which
      is the primary outcome measure will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2012</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sorafenib monotherapy vs. transarterial chemoembolization-sorafenib sequential therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to Feb 28, 2020 (maxium duration: up to 8 years)</time_frame>
    <description>Survival rate during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to Feb 28, 2020 (maxium duration: up to 8 years)</time_frame>
    <description>Time form the enrollment to the event of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to Feb 28, 2020 (maxium duration: up to 8 years)</time_frame>
    <description>Survival rate without progression of HCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival time (MST)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to Feb 28, 2020 (maxium duration: up to 8 years)</time_frame>
    <description>Median time of the patient survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Sorafenib monotherapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The sorafenib monotherapy group receives sorafenib immediately after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-sorafenib sequential therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization (TACE)</intervention_name>
    <description>Standard therapy for intermediate HCC, but nor for advanced HCC</description>
    <arm_group_label>TACE-sorafenib sequential therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Standard therapy for advanced HCC</description>
    <arm_group_label>Sorafenib monotherapy arm</arm_group_label>
    <arm_group_label>TACE-sorafenib sequential therapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hepatocellular carcinoma by the European Association for the Study of
             the Liver (EASL) criteria or pathology

          -  One or more extrahepatic metastatic lesion by proven radiologically or histologically

          -  No serious coagulation abnormalities

          -  Performance status 0 or 1 by Eastern Cooperative Oncology Group(ECOG) criteria

          -  Child-Pugh score 5 or 6

          -  Serum creatinine &lt;1.5mg/dL

          -  Age between 18 ~ 75 years old

          -  No other life-threatening medical illness

        Exclusion Criteria:

          -  Patients with main portal vein invasion

          -  Child-Pugh class B or C

          -  History of TACE or previous systemic chemotherapy including sorafenib

          -  Age &gt;75 years old

          -  Cardiovascular diseases

          -  History of gastrointestinal bleeding within 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <phone>82-31-412-6565</phone>
    <email>gudwns21@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Yim, M.D.</last_name>
      <phone>82-31-412-6565</phone>
      <email>gudwns21@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sang Jun Suh, M.D.</last_name>
      <phone>82-31-412-4926</phone>
      <email>mothpickle@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hyung Joon Yim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Jun Suh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Kul Jung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunghyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Seok Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Jin Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasoon Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Bum Cho, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Marry Hospital, the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Hyun Bae</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Yong Park, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </results_reference>
  <results_reference>
    <citation>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.</citation>
    <PMID>11981766</PMID>
  </results_reference>
  <results_reference>
    <citation>Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002 Jul;224(1):47-54. Review.</citation>
    <PMID>12091661</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429-42. Review.</citation>
    <PMID>12540794</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </results_reference>
  <results_reference>
    <citation>Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.</citation>
    <PMID>21605146</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

